

## Ozoralizumab

|           |   |
|-----------|---|
| Cat. No.: | HY-P99796   |
| CAS No.:  | 1167985-17-2  |
| Target:   | TNF Receptor  |
| Pathway:  | Apoptosis   |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |   |               |  |         |         |                 |                        |         |   |
|--------------------|---|---------------|--|---------|---------|-----------------|------------------------|---------|---|
| <b>Description</b> | Ozoralizumab (ATN-103) is an anti-TNF $\alpha$ humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNF $\alpha$ nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis <sup>[1]</sup> .   |               |  |         |         |                 |                        |         |   |
| <b>In Vitro</b>    | Ozoralizumab (ATN-103; 0-1000 pM; 48 h) has high TNF $\alpha$ -neutralizing potency in the L929 cell cytotoxicity assay with K <sub>D</sub> values of 20.2 pM and 16.1 pM for human TNF $\alpha$ and monkey TNF $\alpha$ , respectively <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.   |               |  |         |         |                 |                        |         |   |
| <b>In Vivo</b>     | Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 human TNF transgenic mice) inhibits arthritis and reduces arthritis scores <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |               |  |         |         |                 |                        |         |   |
|                    | <table border="1"> <tr> <td>Animal Model:</td> <td>Tg197 human TNF transgenic mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection</td> </tr> <tr> <td>Result:</td> <td>Reduced the mean histopathologic score in the Tg197 mice.<br/>Had ability to neutralize TNF<math>\alpha</math> activity.</td> </tr> </table> | Animal Model: | Tg197 human TNF transgenic mice <sup>[1]</sup> | Dosage: | 1 mg/kg | Administration: | Subcutaneous injection | Result: | Reduced the mean histopathologic score in the Tg197 mice.<br>Had ability to neutralize TNF $\alpha$ activity. |
| Animal Model:      | Tg197 human TNF transgenic mice <sup>[1]</sup>  |               |  |         |         |                 |                        |         |   |
| Dosage:            | 1 mg/kg   |               |  |         |         |                 |                        |         |   |
| Administration:    | Subcutaneous injection  |               |  |         |         |                 |                        |         |   |
| Result:            | Reduced the mean histopathologic score in the Tg197 mice.<br>Had ability to neutralize TNF $\alpha$ activity.   |               |  |         |         |                 |                        |         |   |

### REFERENCES

[1]. Ishiwatari-Ogata C, et, al. Ozoralizumab, a Humanized Anti-TNF $\alpha$  NANOBODY<sup>®</sup> Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNF $\alpha$  IgG. Front Immunol. 2022 Feb 22;13:853008.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA